SRR12475117
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.500
- OXIDATIVE_PHOSPHORYLATION+0.300
- ANDROGEN_RESPONSE+0.220
- FATTY_ACID_METABOLISM+0.210
- BILE_ACID_METABOLISM+0.160
- HEME_METABOLISM+0.160
- PANCREAS_BETA_CELLS+0.140
- ADIPOGENESIS+0.130
- ALLOGRAFT_REJECTION+0.110
- GLYCOLYSIS+0.110
Top 10 suppressed
- MYC_TARGETS_V2-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- APICAL_JUNCTION-0.330
- DNA_REPAIR-0.330
- MYOGENESIS-0.330
- TNFA_SIGNALING_VIA_NFKB-0.300
- G2M_CHECKPOINT-0.290
- P53_PATHWAY-0.290
- WNT_BETA_CATENIN_SIGNALING-0.290
- UV_RESPONSE_UP-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R141 | — | — | 0.794 |
| 2 | TCGA-D8-A27E-01A-11R-A16F-07 | — | B | 0.780 |
| 3 | SRR660638 | GTEX | — | 0.771 |
| 4 | s0095142 | — | — | 0.766 |
| 5 | SRR975588 | — | — | 0.764 |
| 6 | MBCProject_1509_T1_RNA | — | B | 0.758 |
| 7 | SRR4296076 | — | cohortA1 | 0.739 |
| 8 | TCGA-A7-A26E-01A-11R-A277-07 | — | D | 0.725 |
| 9 | MBCProject_3946_T5B_RNA | — | C | 0.722 |
| 10 | SRR33346952 | — | — | 0.722 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |